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Abstract
 
Hematopoietic cell growth, differentiation, and chemotactic responses require coordinated ac-
 
tion between cytokines and chemokines. Cytokines promote receptor oligomerization, followed
by Janus kinase
 
 (
 
JAK) kinase activation, signal transducers and transactivators of transcription
 
(
 
STAT) nuclear translocation, and transcription of cytokine-responsive genes. These include
genes that encode a family of negative regulators of cytokine signaling, the suppressors of cy-
tokine signaling (SOCS) proteins. After binding their specific receptors, chemokines trigger re-
ceptor dimerization and activate the JAK/STAT pathway. We show that SOCS3 overexpression
or up-regulation, stimulated by a cytokine such as growth hormone, impairs the response to
CXCL12, measured by Ca
 
2
 
 
 
 flux and chemotaxis in vitro and in vivo. This effect is mediated
by SOCS3 binding to the CXC chemokine receptor 4 receptor, blocking JAK/STAT and G
 
 
 
i
 
pathways, without interfering with cell surface chemokine receptor expression. The data pro-
vide clear evidence for signaling cross-talk between cytokine and chemokine responses in
building a functional immune system.
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Introduction
 
The chemokines comprise a large family of low molecular
weight (8–10 kD) cytokines, with chemotactic and pro-acti-
vatory effects on different leukocyte lineages (1–3). Studies
have established the central role of chemokines in a number
of physiological situations, including T helper responses,
hematopoiesis, angiogenesis, and homeostasis, as well as in
pathological conditions such as asthma, tumor rejection,
HIV-1 infection, and arteriosclerosis (4–8).
Chemokines mediate their biological effects after bind-
ing to specific receptors, members of the seven-transmem-
brane domain G protein–coupled receptor family (1, 2).
Chemokine receptors are promiscuous, as each can bind
more than one chemokine; expression is heterogeneous
among different cells of the leukocyte lineage and is tran-
scriptionally regulated (3, 5). An exception is the CXC
chemokine receptor 4 (CXCR4)
 
*
 
 receptor, which binds
only stromal cell–derived factor (SDF)-1
 
 
 
 (CXCL12) (1,
2), a chemokine isolated from stromal cell culture superna-
tants (9). Its chemotactic properties have been described in
PBLs (10), CD34
 
 
 
 progenitor cells (11), and pre- and pro-
B cell lines (12). Knockout mice lacking the CXCL12 pro-
tein (10) and mice lacking the CXCR4 receptor (13, 14)
display similar phenotypes: animals die before birth, dis-
playing abnormalities in B cell lymphopoiesis and bone
marrow myelopoiesis, lack of blood vessel formation in the
gut, severe ventricular septal defects, and altered cerebellar
neuron migration (13–15).
After binding to their receptors, chemokines trigger re-
ceptor association of guanine nucleotide-binding proteins
(G proteins; reference 16); this activates signaling molecules
that mediate changes in the cytoskeletal apparatus and tran-
scription factors that regulate cell growth (17–19). We have
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shown that CXCL12 (16), as well as other chemokines
such as monocyte chemotactic protein
 
 (
 
MCP)-1 (CCL2)
and regulated upon activation, normal T cell–expressed and
secreted (RANTES; CCL5) (20, 21), exert their effects via
dimerization of their receptors and activation of Janus ki-
nase (JAK) kinases, a protein family originally implicated in
cytokine signaling (22). This in turn phosphorylates the
chemokine receptors in tyrosine residues and activates sig-
nal transducers and transactivators of transcription (STAT)
transcription factors (23).
The suppressors of cytokine signaling (SOCS) family
proteins have been identified as feedback regulators of
JAK/STAT activation, through their binding to JAK ki-
nases or cytokine receptors (24–28). The majority of cyto-
kines analyzed to date, such as LIF, IL-2, IL-3, IL-6,
growth hormone (GH), IFN-
 
 
 
, and leptin, induce several
SOCS family members in a tissue-specific manner (24, 28).
The regulatory role of SOCS molecules is not limited to
the cytokine receptor superfamily, however, as interaction
has been described between SOCS and other cellular tar-
gets, such as the IGF-I receptor, suggesting that SOCS pro-
teins may have an extensive role in receptor signaling (29).
Here we show that through JAK/STAT activation,
CXCR4 occupancy by CXCL12 upregulates a member of
the SOCS protein family, SOCS3. Cytokine-stimulated
overexpression or upregulation of SOCS3 interferes with
signaling by certain chemokines, including CXCL12. By
binding to CXCR4, SOCS3 blocks JAK/STAT com-
plex  activation and association to CXCR4, inhibiting
CXCL12-mediated responses both in vivo and in vitro.
These data, discussed here in the context of cross-talk be-
tween cytokine and chemokine responses, will aid in un-
derstanding the functional role of this chemokine/chemo-
kine receptor pair and add a new element to the complex
function of the immune system.
 
Materials and Methods
 
Biological Materials.
 
IM-9 (ATCC CCL159) and HEK-293
cells (ATCC TIB202) were from the American Type Culture
Collection. Antibodies used include anti-CXCR4 (CXCR4–01)
and anti-hGH receptor (hGHR-05) mAb generated in our labo-
ratory (16, 30), horseradish peroxidase (PO)-labeled anti-PTyr
mAb (4G10; Upstate Biotechnology), anti-phosphothreonine and -
phosphoserine mAb (Calbiochem), anti-
 
 
 
2
 
 microglobulin mAb
(BD Biosciences), anti-Flag M2 mAb (Sigma-Aldrich), anti-
CD71 mAb (Zymed Laboratories), FITC-labeled anti-CD3
(Southern Biotechnology Associates, Inc.), FITC-anti-CD11b
and PE-b220 (BD Biosciences); rabbit anti-PTyr (Promega);
anti-JAK1, -JAK2, and -JAK3 (Upstate Biotechnology); anti-
G
 
 
 
 
 
, -G
 
 
 
s
 
, anti-STAT1 to -STAT6, anti-pol II (Santa Cruz
Biotechnology, Inc.), and anti–
 
 
 
-actin (Sigma-Aldrich). For
immunostaining, we used anti-STAT3 and -phospho-STAT3
antibody (New England Biolabs, Inc.). AG490 and AG9 were
from Calbiochem and pertussis toxin
 
 (
 
Ptx) was from Sigma-
Aldrich.
 
Flow Cytometry Analysis.
 
Cells were centrifuged (250 
 
g
 
, 10
min, room temperature), plated in V-bottom 96-well plates
(2.5 
 
 
 
 10
 
5
 
 cells/well), and incubated with biotin-labeled
hGHR-05 mAb (1 
 
 
 
g/50 
 
 
 
l/well, 60 min, 4
 
 
 
C). Cells were
washed twice in PBS with 2% BSA and 2% FCS and centrifuged
(250 
 
g
 
, 5 min, 4
 
 
 
C). Fluorescein isothiocyanate-labeled strepta-
vidin (Southern Biotechnology Associates, Inc.) was added, in-
cubated (30 min, 4
 
 
 
C), plates washed twice, and cell-bound
fluorescence determined in a Profile XL flow cytometer at 525 nm
(Beckman Coulter).
 
Immunocytochemical Analysis.
 
IM-9 cells were cultured in
RPMI with 1% BSA for 2 h, alone or CXCL12-stimulated (50
nM), washed with PBS at room temperature (RT), fixed with
100% methanol (10 min, 
 
 
 
20
 
 
 
C), and permeabilized with 0.2%
Triton X-100 in TBS (15 min, RT). After washing with TBS
(3
 
 
 
, 5 min, RT), nonspecific binding sites were blocked with 5%
goat serum in TBS (45 min, RT). Cells were washed with TBS,
then incubated with anti-STAT3 or anti-phospho-STAT3 mAb
diluted in TBS, 2% BSA, 2% normal goat serum, followed by
Cy3-labeled anti–rabbit IgG antibody (Jackson ImmunoResearch
Laboratories). Vectashield mounting medium with 4
 
 
 
,6-diami-
dino-2-phenylindole (DAPI; Vector Laboratories) was added and
cells analyzed in a Leica fluorescence microscope.
 
Cell Migration.
 
Cells were placed (0.25 
 
 
 
 10
 
6
 
 cells in 0.1 ml)
in the upper well of 24-well transmigration chambers (5 
 
 
 
m
pore; Transwell; Costar Corp.) whose membrane was precoated
with type VI collagen (20 
 
 
 
g/ml; Sigma-Aldrich); 50 nM
CXCL12 or 10 nM CCL20 (in 0.6 ml RPMI with 0.25% BSA;
PeproTech) was then added to the lower well. Plates were incu-
bated (120 min, 37
 
 
 
C) and cells that migrated to the lower cham-
ber were counted as described (23). When recombinant hGH
(Genotropin; Pharmacia AB) treatment was used, cells (10
 
6
 
/ml)
were incubated in RPMI 1640 with 0.1% BSA and 10 
 
 
 
g/ml
hGH for the time indicated.
To evaluate primary cells, mouse spleen, lymph node, and
bone marrow cells (0.25 
 
 
 
 10
 
6
 
 cells in 0.1 ml) were placed in the
upper well of 24-well transmigration chambers (3 
 
 
 
m pore;
Transwell) as described above. In spleen and bone marrow cell
preparations, erythrocytes were lysed with NH
 
4
 
Cl (5 min, 37
 
 
 
C).
In assays in which depletion of fresh isolated primary cells was
necessary, cells were plated (10
 
6
 
 cells in 1 ml) in RPMI 1640 sup-
plemented with 0.1% BSA and cultured (2 h, 37
 
 
 
C). After wash-
ing, migration in response to CXCL12 was evaluated as above.
HEK-293 cell migration was studied in a 96-well microcham-
ber (NeuroProbe Inc.; reference 31). Chemokines at several con-
centrations were loaded into lower wells (30 
 
 
 
l/well), and cells
(200 
 
 
 
l/well, 3 
 
 
 
 10
 
6
 
 cells/ml) in upper wells. Polyvinylpyrroli-
done-free filters (10 
 
 
 
m pore; NeuroProbe Inc.) were precoated
(2 h, 37
 
 
 
C) with 20 
 
 
 
g/ml type VI collagen (Sigma-Aldrich).
The chamber was incubated (5 h, 37
 
 
 
C), after which filters were
removed and the cells on the upper part wiped off. Cells on the
filters were fixed and stained (0.5% crystal violet, 20% methanol).
Blue spots developed at positions at which cell migration had oc-
curred, allowing densitometric quantitation of migration (Na-
tional Institutes of Health Image software). The migration index
was calculated by mean spot intensity.
 
In Vivo Biological Activity of CXCL12.
 
3-mo-old bGH-trans-
genic (Tg) and non-Tg littermate mice received intraperitoneal
injection of CXCL12 (1 
 
 
 
g in 400 
 
 
 
l sterile PBS) or PBS alone.
Mice were killed 6 h after injection and migrated cells extracted
from the peritoneal cavity by injecting 6 ml of sterile PBS. Cells
were counted, centrifuged (250 
 
g
 
, 10 min), and the distinct cell
populations enumerated by flow cytometry analysis using specific
cell surface markers. Migration is calculated for each cell popula-
tion from CXCL12-treated mice as the 
 
x
 
-fold increase over neg-
ative control (PBS-treated mice). 
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Immunoprecipitation, SDS-PAGE, and Western Blot Analysis.
 
CXCL12-stimulated cells (10 
 
 
 
 10
 
6
 
) were lysed in detergent
buffer (20 mM triethanolamine, pH 8.0, 300 mM NaCl, 2 mM
EDTA, 20% glycerol, 1% digitonin, with 10 
 
 
 
M sodium ortho-
vanadate, 10 
 
 
 
g/ml leupeptin, and 10 
 
 
 
g/ml aprotinin; 30 min,
4
 
 
 
C, continuous rocking), then centrifuged (15,000 
 
g
 
, 15 min).
Immunoprecipitation was as described (16); protein G-Sepharose
was used to analyze SOCS3 immunoprecipitates. Precipitates or
protein extracts were separated in sodium dodecyl sulfate PAGE
(SDS-PAGE) and transferred to nitrocellulose membranes.
Western blot analysis was as described (16), using 2% BSA in
TBS as blocking agent for anti-phosphotyrosine analyses. To
strip, membranes were incubated (60 min, 60
 
 
 
C) with 62.5 mM
Tris-HCl, pH 7.8, containing 2% SDS and 0.5% 
 
 
 
-mercapto-
ethanol. Protein loading was controlled using a protein detection
kit (Pierce Chemical Co.) and, when necessary, by reprobing the
membrane with the immunoprecipitating antibody. For drug
treatment, cells were incubated (16 h, 37
 
 
 
C) with Ptx (0.1 
 
 
 
g/
ml) and AG490 or AG9 (50 
 
 
 
M). When necessary, quantitation
was performed using the National Institutes of Health Image
software.
 
Preparation of Nuclear Extracts.
 
Nuclear extracts were pre-
pared from CXCL12-stimulated IM-9 cells (10 
 
 
 
 10
 
6
 
; refer-
ence 16). Cells were washed with ice-cold PBS, resuspended in
1 ml of buffer A (50 mM NaCl, 0.5 M sucrose), incubated (2
min, 4
 
 
 
C), and pelleted (4,500 
 
g
 
, 3 min, 4
 
 
 
C). They were then
resuspended in 1 ml of buffer B (50 mM NaCl, 25% glycerol),
pelleted (4,500 
 
g
 
, 3 min, 4
 
 
 
C), and incubated in 60 
 
 
 
l of buffer C
(350 mM NaCl, 25% glycerol) for 30 min at 4
 
 
 
C with continu-
ous rocking. After centrifugation (20,000 
 
g
 
, 20 min, 4
 
 
 
C), super-
natants containing nuclear extracts were aliquoted and stored at
 
 
 
80
 
 
 
C. All buffers contained 0.5 mM spermidine, 0.15 mM
spermine, 0.1 mM EDTA, 10 mM HEPES, pH 8, 0.5 mM
PMSF, 2 
 
 
 
g/ml leupeptin, 3 
 
 
 
g/ml pepstatin, 0.2 IU/ml aproti-
nin, 1.75 mM 
 
 
 
-mercaptoethanol, 1 mM orthovanadate, and 10
mM NaF. Nuclear extract (20 
 
 
 
g) was separated in SDS-PAGE
and transferred to nitrocellulose membranes for Western blot
analysis, performed as above, and developed with anti-STAT3
and -STAT5b antibodies.
 
Electrophoretic Mobility Shift Assay.
 
Nuclear extracts (10 
 
 
 
g),
prepared as above from untreated or chemokine-treated cells,
were analyzed in binding reactions. Extracts were incubated with
0.5 ng 
 
32
 
P-end-labeled double-stranded oligodeoxynucleotides
containing the sis-inducible element (SIE) of the c-fos promoter
sequence (GGGGTGCATTTCCCGTAAATCTTGTCT) (wild
type; wt-SIE); where indicated, a mutant version was used that
is unable to bind STAT proteins (GGGGTGCATCCACCG-
TAAATCTTGTCT) (mut-SIE). The binding reaction was per-
formed in electrophoretic mobility shift assay (EMSA) buffer (30
min, RT; final volume 10 
 
 
 
l) with 1.5 
 
 
 
g poly(dI-dC) and,
where indicated, a 20-fold molar excess of unlabeled SIE or non-
specific oligonucleotide competitor. Protein–DNA complexes
were resolved on a 4.5% polyacrylamide gel using 0.5
 
 
 
 Tris-
borate-EDTA running buffer. EMSA buffer contained 10 mM
Tris, pH 7.5, 50 mM NaCl, 1 mM dithiothreitol, 1 nM EDTA,
and 5% glycerol. Protein amount in nuclear extracts was con-
firmed before Western blot or EMSA using a protein detection
kit (Pierce Chemical Co.).
 
Cell Transfection.
 
Human embryonic kidney cells (HEK-
293) were transiently transfected with pEF-Flag-I/mSOCS1,
mSOCS2, or mSOCS3 constructs (donated by Dr. T. Willson,
Walter and Eliza Hall Institute of Medical Research, Victoria,
Australia) using lipofectamine (GIBCO BRL) according to the
 
manufacturer’s protocol. When required, IM9 cells or CCR6-
stably transfected BaF/6 cells (32) were transiently transfected
by electroporation (12 
 
 
 
 10
 
 
 
6
 
 cells/500 
 
 
 
l Optimem, 280 V,
975 mF).
 
RNA Interference.
 
We synthesized a silent RNA (siRNA) se-
quence targeting SOCS3 position 80–101 relative to the start
codon, and a scrambled siRNA duplex as control (Dharmacon
Research). For transfection, we used 1.2 
 
 
 
M of the siRNA or 20
 
 
 
g of the pEF-Flag-I/mSOCS3 construct. Cell migration was
evaluated as described 48 h after electroporation. Transfection ef-
ficiency was controlled by evaluating SOCS3 mRNA in North-
ern blot.
 
Northern Hybridization.
 
Total RNA from 3-mo-old bGH Tg
and non-Tg littermate mouse tissues and IM-9 cells, untreated or
treated (60 min, 37
 
 
 
C) with 60 nM CXCL12 or 10 
 
 
 
g/ml GH,
was extracted using Tri-reagent (Sigma-Aldrich). RNA samples
were resolved on denaturing formaldehyde-agarose gels and
transferred to nylon membrane (Hybond N
 
 
 
; Amersham Bio-
tech). Membranes were hybridized with 
 
32
 
P-labeled cDNA from
the pEF-Flag-I/mSOCS3 construct.
 
Results
 
CXCL12-induced SOCS3 Up-regulation Inhibits Functional
CXCR4 Activity.
 
The human IM-9 B cell line responds
to CXCL12 through CXCR4-mediated Ca
 
2
 
 
 
 mobilization
and cell migration (see below). As for other cell lineages
(16), pretreatment with AG490, a specific JAK inhibitor,
completely abrogates CXCL12-mediated responses (Fig. 1
A), suggesting JAK involvement. CXCL12 promotes JAK1
and JAK3 association with CXCR4 (Fig. 1 B), followed by
their rapid tyrosine phosphorylation (Fig. 1 C). As a conse-
quence, STAT1, -2, -3, and -5, but not STAT4 or -6, are
also activated, indicated by their association to CXCR4
(not shown) and their phosphorylation pattern (Fig. 2, A
and B). As in the case of the cytokines (33), CXCL12 also
promotes Ser/Thr phosphorylation of STAT. Using spe-
cific antibodies, we found that STAT3 is Ser/Thr phos-
phorylated after stimulation with CXCL12, and that the
kinetics correlate with its tyrosine phosphorylation (Fig. 2
C); in both cases, maximum phosphorylation occurs 15
min after stimulation.
Nuclear extracts of CXCL12-stimulated IM-9 cells were
analyzed in Western blot using anti-STAT antibodies, and
maximum nuclear translocation was observed 30 min after
activation (Fig. 2 D, top). Nuclear extracts analyzed in
Western blot using anti-pol II antibody as a nuclear marker
(Fig. 2 D, bottom) were free of cytoplasmic contamination,
confirmed by developing with an anti–
 
 
 
-actin cytoplasmic
marker antibody (not shown). As predicted, SIE binding
activity was detected after chemokine treatment, measured
by EMSA (Fig. 2 E). Protein levels in nuclear extracts were
controlled using a protein detection kit. We thus con-
cluded that CXCL12 triggers JAK/STAT pathway activa-
tion and the nuclear translocation of STAT.
Cytokine activation of the JAK/STAT pathway leads to
SOCS up-regulation, implicated in turn in the negative
feedback of cytokine signaling. We tested whether SOCS
are up-regulated as a consequence of CXCL12-induced314 SOCS3 Inhibits CXCL12 Signal Transduction
STAT translocation in IM-9 cells. Only SOCS3 was de-
tected in lysates of CXCL12-stimulated IM-9 cell analyzed
in Western blot using anti-SOCS antibodies (Fig. 3 A, left;
maximum at 60 min). Pretreatment of IM-9 cells with the
JAK kinase inhibitor AG490 (10 nM, overnight, 37 C), but
not with control AG9 (not shown), abrogated CXCL12-
mediated SOCS3 up-regulation (Fig. 3 A, center); none-
theless, PTx treatment (0.1  g/ml, overnight, 37 C) had
no effect (Fig. 3 A, right). These data indicate that
chemokine-induced SOCS3 up-regulation is independent
of Gi activation, and confirm previous results showing in-
dependence between JAK/STAT activation and the G
protein pathway in chemokine signaling (23).
To evaluate the role of SOCS3 up-regulation in the con-
trol of CXCL12 responses, HEK-293 cells transiently trans-
fected with pEF-Flag-I/mSOCS1, /mSOCS2, or /mSOCS3
constructs were allowed to migrate in response to a
CXCL12 gradient. Whereas there was no influence on
migration of SOCS2-expressing cells, we observed a clear
reduction in the migration index in SOCS1- and SOCS3-
expressing cells (Fig. 3 B, top). SOCS expression was con-
trolled in each experiment by Western blot of cell lysates
with anti-Flag antibody (Fig. 3 B, bottom). Potential toxic
effects of SOCS overexpression were discarded by analyz-
ing cell incorporation of propidium iodide in flow cytoflu-
orometry (not shown). To test the specificity of SOCS ef-
fects on chemokine receptors, SOCS3 was overexpressed
Figure 1. CXCL12 induces JAK activation in IM-9 cells. (A)
CXCL12-induced chemotaxis of IM9 cells, untreated or pretreated
with AG490 or tyrphostin A1, was assayed in transwell chemotaxis
chambers. Results are expressed as a migration index, calculated as the
x-fold increase over the negative control. Mean   SD of five experi-
ments is shown. (B) CXCL12 (50 nM)-induced IM-9 cell lysates were
immunoprecipitated with anti-CXCR4 mAb or mouse IgM as a con-
trol, and tested in Western blot with anti-JAK1, -JAK2, or -JAK3 anti-
bodies, as indicated. Equivalent receptor loading was controlled by re-
probing each membrane with CXCR4–01 mAb. As a positive control,
unprecipitated IM-9 cell lysates were tested in Western blot with anti-
JAK antibodies. (C) CXCL12-activated IM-9 cell lysates as in B were
immunoprecipitated with anti-PTyr antibodies and analyzed in Western
blot with anti-JAK1 and -JAK3 antibodies. Equivalent protein loading
in each lane was controlled.
Figure 2. CXCL12 induces activation of STAT transcription factors in
IM-9 cells. (A) STAT phosphorylation was determined in stimulated cell
lysates immunoprecipitated with anti-Ptyr as in Fig. 1 C, and assayed in
Western blot with anti-STAT3 or STAT5b antibodies. Equal protein
loading was controlled. (B) Immunohistochemical analysis of IM-9 cells,
untreated or treated with CXCL12, using anti-STAT3 and anti-PTyr-
STAT3 antibodies. Nuclear staining is shown (insets). (C) STAT2 and
STAT3 Ser/Thr phosphorylation was measured in lysates of CXCL12-
activated IM-9 cells immunoprecipitated with anti-PSer/PThr and assayed
in Western blot with anti-STAT2 and -3 antibodies. (D) IM-9 cells were
stimulated with CXCL12 at the times indicated and nuclear extracts ana-
lyzed in Western blot using anti-STAT2 and –5b antibodies. Membranes
were developed with anti-pol II antibodies to control equivalent protein
loading. (E) Nuclear extracts of untreated or CXCL12-treated IM-9 cells
were incubated with 32P-end-labeled wt-SIE in EMSA buffer. Where in-
dicated, a 20-fold molar excess of unlabeled wt-SIE or mut-SIE oligonu-
cleotide was added.315 Soriano et al.
in CCR6-stably transfected BaF/3 cells (32). Whereas
CXCL-12-mediated migration of these cells was com-
pletely abrogated by SOCS overexpression, migration
through a CCL20 gradient was unaffected (Fig. 3 C). As a
control, SOCS3 expression was determined as before in
each experiment by Western blot (not shown). These data
indicate that SOCS3 and SOCS1 are negative regulators of
CXCL12 signaling, opening a route for cross-talk between
chemokine and cytokine signals. Although SOCS3 expres-
sion does not alter CCR6-mediated migration, we cannot
exclude potential control of CCR6 or other chemo-
kine receptors by other SOCS proteins. To evaluate the
mechanism involved in these SOCS effects, HEK-293
cells transiently transfected with pEF-Flag-I/mSOCS1,
/mSOCS2, or /mSOCS3 constructs, untreated or
CXCL12-stimulated, were lysed and cell extracts immu-
noprecipitated using CXCR4–01 mAb. Western blot
analysis of the immunoprecipitates with an anti-Flag anti-
body showed that SOCS1 and SOCS3, but not SOCS2,
associate to CXCR4; this association increases when cells
are activated by CXCL12 (Fig. 3 D). As a protein loading
control, membranes were reprobed with the CXCR4–01
mAb. The data indicate that SOCS interfere with chemo-
kine-mediated responses by binding to their receptors,
blocking JAK/STAT pathway activation. These results,
and the fact that CXCL12 up-regulation of SOCS3 re-
quires long stimulation periods, exclude SOCS involve-
ment in CXCR4 desensitization, a rapid process involving
GRK and arrestin (34).
GH Blocks CXCL12-mediated Signaling. We examined
whether cytokine-induced SOCS3 upregulation affects
CXCL12 signaling. GH mediates SOCS3 up-regulation
by activating the JAK2/STAT5b pathway, which modu-
lates later effects of the hormone (35). As IM-9 cells have
surface GH receptors (Fig. 4 A), we used GH as a model
to evaluate time-dependent SOCS3 up-regulation. Up-
regulation was observed in lysates of GH-treated IM-9
cells analyzed in Western blot using anti-SOCS antibodies,
with maximum effect at 60 min of treatment (band inten-
sity 4.9-fold greater than control values), which concurs
with the period observed for other cytokines (36; Fig. 4
B). As a consequence of GH activation, SOCS3 up-regu-
lation again has functional consequences, as Ca2  and mi-
gratory responses to CXCL12 are seriously impaired in
GH-pretreated IM-9 cells (Fig. 4, C and D), although GH
does not promote Ca2  or migratory responses. As in the
case of HEK-293 cells, transient SOCS3 transfection in
IM-9 cells also abolished CXCL12-mediated responses
(Fig. 4 D, left). To confirm these data, we specifically si-
lenced SOCS3 gene expression using RNA interference
(37; Fig. 4 D, bottom right). Under these conditions, GH
treatment does not induce SOCS3 up-regulation, and
CXCL12-mediated responses are thus unaffected (Fig. 4
D, top right).
GH treatment does not modify surface CXCR4 levels,
shown by flow cytometry analysis using anti-CXCR4 mAb
(Fig. 5 A). GH pretreatment also prevents CXCL12-medi-
ated CXCR4 internalization (Fig. 5 A), indicating that GH
interferes with CXCL12 signaling rather than with surface
CXCR4 levels. To test the mechanism by which SOCS3
interferes with chemokine signaling in a system using non-
transfected cells, anti-SOCS3 immunoprecipitates of IM-9
cells, untreated or GH-pretreated (60 min, 37 C), were an-
alyzed in Western blot using anti-CXCR4 mAb. GH treat-
ment up-regulates SOCS3, shown by Western blot analysis
Figure 3. CXCL12-induced SOCS expression blocks CXCL12-
induced cell responses. (A) Lysates from IM-9 cells, untreated or pre-
treated with AG490 or PTx and stimulated with 50 nM CXCL12, were
immunoblotted with anti-SOCS3 antibody. Protein loading was con-
trolled by reprobing the membrane with anti-  actin mAb. (B) pEF-Flag-
I/mSOCS1-, mSOCS2-, and mSOCS3-transfected HEK-293 cells or
mock-transfected controls were allowed to migrate in response to
CXCL12. A representative experiment is shown (mean   SD, n   3 rep-
licates) of five performed (top). SOCS expression in migrating cells was
confirmed by Western blot of transfected cell lysates with anti-Flag anti-
body (bottom). (C) CCR6-BaF/3 cells were transfected with pEF-Flag-I/
mSOCS3 and allowed to migrate in response to CXCL12 or CCL20.
Mock-transfected cells were used as a control. A representative experi-
ment is shown (mean   SD, n   3 replicates) of four performed. (D) Ly-
sates of pEF-Flag-I/mSOCS1-, mSOCS2-, and mSOCS3-transfected
HEK-293 cells or mock-transfected controls, untreated or CXCL12-
stimulated, were immunoprecipitated using CXCR4–01 mAb and ana-
lyzed in Western blot with the anti-Flag mAb. As control, the membrane
was reprobed using the CXCR4–01 mAb.316 SOCS3 Inhibits CXCL12 Signal Transduction
using anti-SOCS3 antibodies (Fig. 5 B, bottom), and
SOCS3 binds the chemokine receptor (Fig. 5 B, top). This
association increases following CXCL12 binding, indicating
that the chemokine promotes a conformational change in
the CXCR4 that exposes or stabilizes a SOCS3 binding site
(Fig. 5 B, top). As a control, the membrane was reprobed
with an anti-transferrin receptor mAb (CD71), showing
specificity of the SOCS3/CXCR4 association (Fig. 5 B,
center). As JAK and Gi protein activation are two of
the earliest events in chemokine signaling, we analyzed
CXCL12-induced association of these two proteins to
CXCR4 under conditions in which SOCS3 is up-regu-
lated. Serum-starved IM-9 cells, untreated or GH-treated,
were CXCL12-stimulated at different times; cell lysates
were immunoprecipitated using anti-CXCR4 antibody and
Figure 4. GH treatment affects CXCL12-mediated responses. (A)
hGHR levels were measured by flow cytometry in IM-9 cells incubated
with biotin-labeled hGHR-05 mAb, followed by FITC-streptavidin.
mAb binding is compared with that of a negative control (mIgM). (B)
GH-activated IM-9 cell lysates were analyzed in Western blot with anti-
SOCS3 antibody. Protein loading was controlled by reprobing the mem-
brane with anti-  actin mAb. Data were quantitated using NIH software,
normalized using the signal of an unrelated band, and represented as the
x-fold increase compared with unstimulated cells. (C) CXCL12- or GH-
induced Ca2  mobilization in IM-9 cells, untreated or GH-pretreated,
was measured in flow cytometry. (D) Untreated or GH-treated IM-9
cells were allowed to migrate in response to 50 nM CXCL12 (left). Cells
that migrated to the lower chamber were counted and expressed as a mi-
gration index. Data represent the mean of triplicate determinations, with
SD indicated. IM-9 cells transfected with pEF-Flag-I/mSOCS3, a siRNA
sequence targeting SOCS3, or a scrambled siRNA, were left untreated or
GH-treated (60 min, 37 C) and allowed to migrate in response to 50 nM
CXCL12 as before (top right). To control SOCS3 silencing, mRNA was
extracted from untreated or GH-treated cells previously transfected with a
siRNA sequence targeting SOCS3, or with scrambled siRNA. SOCS3
mRNA was analyzed in Northern blot (bottom right).
Figure 5. GH treatment blocks CXCL12-mediated signaling without
affecting surface CXCR4 levels. (A) Surface CXCR4 levels were ana-
lyzed in IM-9 cells treated with GH, CXCL12, or GH followed by
CXCL12. CXCR4 was measured by flow cytometry with CXCR4–01
mAb and PE-anti–mouse IgM, and is expressed as a percentage of recep-
tor in untreated cells (none) with SD indicated. (B) Lysates of CXCL12-
activated IM-9 cells, untreated (medium) or pretreated for 60 min with
GH (10  g/ml) were immunoprecipitated with anti-SOCS3 antibody
and the Western blot developed with anti-CXCR4 mAb, anti-transferrin
receptor (CD71), or anti-SOCS3 antibody. CXCR4 and CD71 protein
expression was controlled in unprecipitated IM-9 cell lysates with the
corresponding antibody. (C) Lysates of CXCL12-activated IM-9 cells,
untreated or GH-treated, were immunoprecipitated with CXCR4–01 or
control mIgM mAb and the Western blot developed with anti-G i anti-
body. Unprecipitated IM-9 cell lysates were controlled with anti-G i an-
tibody. To verify equal protein loading, the membrane was reprobed
with CXCR4–01 mAb. (D) Cell lysates treated and precipitated as in C
were immunoblotted with anti-JAK3 antibody. Unprecipitated IM-9 cell
lysates were controlled with anti-JAK3 antibody; equal protein loading
was verified as in C.317 Soriano et al.
immunoblotted with specific anti-G i (Fig. 5 C) and -JAK3
antibodies (Fig. 5 D). This experiment showed that GH-
induced SOCS3 up-regulation blocks both JAK3 and G i
association to the CXCR4. Protein loading equivalence
was controlled by reprobing membranes with anti-CXCR4
antibody. The data indicate that SOCS3 affects CXCL12-
mediated responses; by binding to CXCR4, SOCS3 blocks
JAK/STAT pathway activation without affecting cell sur-
face CXCR4 levels.
SOCS3 Blocks CXCL12-mediated Responses In Vivo.
We then explored whether CXCL12-mediated responses
are affected in cells that coexpress GHR and CXCR4, ob-
tained from transgenic mice expressing a fusion gene cod-
ing for bovine GH (bGH-Tg; reference 38). It was previ-
ously determined that B cell numbers in bGH-Tg mouse
spleen increased two- to fourfold, with a lesser increase in
T cells. Some differences were also found in peripheral
lymph nodes, in which B cells increased fivefold in bGH-
Tg mice. Analysis of bone marrow cells showed that bGH-
Tg mice are deficient in pre–B cells, whereas B cell num-
bers are preserved (38). CXCL12 was injected into the
peritoneal cavity of bGH-Tg mice and control littermates;
after 6 h, migrating cells were recovered and analyzed by
flow cytometry using specific cell markers. In CXCL12-
injected bGH-Tg mice, B cell and granulocyte/macro-
phage recovery is impaired compared with wild-type mice,
shown by double staining with B220/CD45 and CD11b/
CD45, respectively (Fig. 6 A). In contrast, T lymphocyte
recovery is unimpaired, shown by CD3/CD45 double
staining (not shown).
Figure 6. bGH-Tg mice have an impaired chemotactic response to CXCL12. (A) CXCL12 (1  M) was injected intraperitoneally in bGH-Tg mice or
control littermates. After 60 min, cells that had migrated into the peritoneal cavity were recovered and the populations characterized by flow cytometry
using specific cell markers. The figure shows specific staining of b220/CD45 and CD11b/CD45 cells; the percentage of each population is also indicated.
Results are shown of one representative experiment of five performed. (B) CXCL12-mediated cell migration of spleen, lymph node, and bone marrow
cells from bGH-Tg mice or wild-type littermates were evaluated in 24-well transmigration chambers; migration was calculated as in Fig. 1 A. Data rep-
resent the mean   SD of triplicate determinations. (C) Northern analysis of SOCS3 mRNA from spleen, lymph node, and bone marrow of bGH-Tg
mice compared with control littermates. As a control, the membrane was rehybridized with eF1 . (D) mRNA was extracted from bone marrow cells of
bGH-Tg mice and control littermates, undepleted or GH-depleted in vitro, and SOCS3 analyzed in Northern blot. Loading was controlled as in C. (E)
Bone marrow cells from mice as in D, undepleted (open symbols) or GH-depleted (filled symbols), were allowed to migrate in response to CXCL12.
Migration was calculated as in Fig. 1 D. Data represent the mean   SD of triplicate determinations.318 SOCS3 Inhibits CXCL12 Signal Transduction
The percentage of B220lowCD45  cells recovered from
the peritoneal cavity of wild-type mice is markedly in-
creased after CXCL12 treatment (5   0.3-fold) compared
with PBS-treated controls. In contrast, no increase was ob-
served in this cell population in CXCL12-treated bGH-Tg
mice (0.73   0.06-fold). Analysis showed that CD11b 
CD45  cells also accumulate in the peritoneal cavity
of CXCL12-treated wild-type mice (3.8   0.2-fold),
whereas moderate migration was observed in treated
bGH-Tg mice (2.07   0.2-fold). No notable differences
were found for B220highCD45   cells from CXCL12-
treated bGH-Tg mice (2.8   0.2-fold) and wild-type mice
(3.2    0.3-fold; Fig. 6 A). A similar effect is observed
when spleen, lymph node, and bone marrow cells from
3-mo-old bGH-Tg mice are allowed to migrate in vitro
toward a CXCL12 gradient. Whereas control non-Tg
mouse cells respond normally to CXCL12, bGH-Tg cells
showed a marked decrease in migration (Fig. 6 B). North-
ern blot analysis showed that bGH-Tg mouse spleen,
lymph node, and bone marrow cells express higher SOCS3
levels than those from non-Tg littermates (Fig. 6 C).
When SOCS3 levels were reduced by in vitro depletion
(120 min) of bone marrow cells from bGH-Tg mice in
GH-free medium (Fig. 6 D), their migratory response to
CXCL12 was restored compared with undepleted cells
(Fig. 6 E), indicating that SOCS3 has a critical role in che-
mokine response regulation. All together, these results as-
sign a direct role to the SOCS proteins in controlling che-
motactic responses to CXCL12 and expose new aspects of
the relationship between cytokines and chemokines in im-
mune response control.
Discussion
Functional lymphoid microenvironments, organogen-
esis, and leukocyte patrolling are established by cell mi-
gration. This requires the integrated action of cell surface
ligands such as integrins and selectins, with soluble medi-
ators including cytokines, chemokines, and their recep-
tors. Whereas the former group participates in rolling
and cell adhesion, the latter has a key role in the lympho-
hematopoiesis and cell polarization required for cell mo-
tility (39). In addition to their selective role under physi-
ological conditions, chemokines also have an important
function in inflammation, wound healing, and angiogen-
esis (6).
In recent years it has been established that hematopoi-
etic cell growth, differentiation, and function are con-
trolled by the coordinated action of the cytokine–chemo-
kine network (40). After cytokine binding to its receptor
on the cell surface, receptor oligomerization takes place,
inducing JAK kinase activation. The activated JAK ki-
nases then phosphorylate the cytokine receptors, leading
to recruitment and subsequent activation of other signal-
ing molecules, such as the STAT family proteins. Acti-
vated STAT proteins translocate to the nucleus and medi-
ate transcription of a range of cytokine-responsive genes
(22), including those that code for the SOCS proteins.
These molecules have recently attracted interest, as they
exercise their effect directly on the JAK/STAT pathway.
Indeed, the majority of cytokines analyzed to date, such as
LIF, IL-2, IL-3, IL-6, GH, IFN- , and leptin, induce
several SOCS family members in a tissue-specific manner
(28).
Much like cytokines, the chemokines trigger oligomer-
ization of their receptors and activation of the JAK/STAT
pathway (31, 41, 42). The similarity among chemokine re-
ceptors, including conservation of the DRY motif, sug-
gests that oligomerization and JAK/STAT pathway activa-
tion are not exclusive to CCR2, in which they were first
described (20, 23); CCR5 and CXCR4 both activate sev-
eral JAK/STAT family members in a cell lineage–depen-
dent fashion. Agonist-induced dimerization has been
described for other GPCR receptors, including the  2-
adrenergic (43), opioid (44), and  -amino butyric acid
(GABA) receptors (45); furthermore, the angiotensin II
(46), TSH (47), and  -melanocyte-stimulating hormone
( -MSH) receptors (48) not only dimerize but also activate
the JAK/STAT pathway.
As described for cytokines (25, 26), CXCL12-medi-
ated STAT activation and nuclear translocation promote
SOCS3 protein up-regulation. By binding to the CXCR4,
overexpressed SOCS1 or SOCS3 proteins prevent a
chemotactic response to CXCL12 in HEK-293 cells. This
is comparable to previous reports of SOCS3 association to
other transmembrane receptors (49–51); here, the conse-
quence is blockade of JAK and Gi association to CXCR4
and impaired chemotactic responses. CXCL12-mediated
SOCS3 up-regulation depends directly on JAK/STAT
pathway activation, as AG490 treatment completely elimi-
nates SOCS3 in lysates of CXCL12-stimulated cells. PTx
treatment does not affect SOCS3 up-regulation, however,
indicating that JAK/STAT activation is G protein pathway
independent. These data, together with the observation
that both PTx and AG490 treatments block CXCL12-
mediated responses, suggest that JAK activation is a very
early event in chemokine signaling. The data confirm our
previous finding that AG490 treatment of Mono Mac-1
cells inhibits JAK and Gi association to the CCR2b recep-
tor after CCL2 binding, whereas PTx does not affect JAK
association (23). The time course of CXCL12-mediated
SOCS3 up-regulation excludes the role of these suppressor
molecules in the rapid ligand-triggered desensitization of
chemokine receptors, which requires GRK and arrestin re-
cruitment (34).
SOCS blockade of chemokine responses may thus be
environmentally influenced, as the presence of other che-
mokines and/or cytokines alters these responses. Although
more exhaustive study is required, preliminary data show
that, as for cytokines (28), SOCS3 blockage selectively af-
fects the responses of certain chemokines without interfer-
ing with others. We nonetheless cannot exclude the in-
volvement of other SOCS family members in the control
of chemokine signals, in which case the specificity of the
effect would depend on differential SOCS protein expres-
sion in diverse cell types. A distinct SOCS expression pat-319 Soriano et al.
tern has been described that correlates with differentiation
into Th1 or Th2 phenotype (52).
GH belongs to the cytokine family, which also com-
prises placental lactogen and prolactin; its biological effects
vary widely, and include skeletal growth during childhood
and regulation of a variety of anabolic processes in adult
life. Lymphocytes also have GH receptors, as defined by
biochemical, molecular, and functional evidence, and GH
has been implicated as a growth and differentiation factor
in the hematopoietic system (53). After binding GH, the
receptor dimerizes and signals through JAK2 kinase (35).
This pathway includes tyrosine phosphorylation of several
proteins, among them the latent cytoplasmic transcription
factors, STATs. This activation leads to upregulation of a
variety of genes in vivo and in vitro, including SOCS2,
SOCS3, and CIS mRNA (54). SOCS inhibit receptor sig-
naling to STAT5b via phosphotyrosine-dependent binding
interactions with the tyrosine kinase JAK2 (SOCS1) and/
or the cytoplasmic tail of GHR (CIS and SOCS3; refer-
ence 55).
Given the ability of both GH and CXCL12 to stimulate
the JAK/STAT pathway and to upregulate SOCS3, we
studied the relationship between chemokines and cyto-
kines using CXCL12 and GH as a model. We show that
the IM-9 cell line does not migrate in response to GH,
but does so in response to CXCL12, a process that is
blocked by pretreatment with the JAK2-specific inhibitor
AG490. When cells were pretreated with GH under con-
ditions that up-regulate SOCS3, cell migration to a
CXCL12 gradient was impaired; when SOCS3 was
downregulated or its expression silenced by RNA inter-
ference (37), however, the chemotactic response was
recovered. These data concur with the absence of a che-
motactic response to CXCL12 in SOCS3-transfected
HEK-293 cells. GH does not affect membrane CXCR4
levels, shown by anti-CXCR4 staining of GH-treated
cells. SOCS3 is nonetheless associated to CXCR4 under
conditions in which it is up-regulated by GH treatment of
IM9 cells. This association increases after CXCL12 stimu-
lation, indicating that the ligand may promote conforma-
tional changes in the CXCR4, which then exposes the
SOCS3 binding site or stabilizes the complex. As a conse-
quence, neither JAK nor Gi associates to the CXCR4,
blocking chemotactic responses; a model is outlined in
Fig. 7. The data thus indicate that CXCL12 is able to acti-
vate CXCR4 under conditions in which SOCS3 is up-
regulated, not only in vitro but also in vivo, as observed in
bGH-Tg mice. These mice, which have altered hemato-
poiesis, show a defective CXCR4 response in cells ex-
pressing the GH receptor, compatible with the high
SOCS3 levels in these cells. As predicted, similar cell pop-
ulations in wild-type littermates show no SOCS3 up-reg-
ulation and thus have normal responses to CXCL12.
Furthermore, when bGH-Tg mouse cells are depleted
of growth factor in vitro, SOCS3 levels diminish and
CXCL12-mediated responses are restored.
Identification of the chemokine-activated JAK/STAT/
SOCS pathway has opened a new avenue in signal trans-
duction research, by integrating this pathway with those
of cytokine signaling. It is now of interest to identify the
cytokine/chemokine combination and the SOCS expres-
sion pattern required by each lineage during develop-
ment, as well as those of cells mobilized in normal im-
mune responses and the inflammatory response. In vivo
experiments indicate a possible role for such interactions,
as neutrophils purified from acromegalic or hyperpro-
lactinemic individuals show decreased in vitro chemotaxis
to an N-formylmethionyl-phenylalanine gradient (56).
Chemokine response defects may also collaborate in the
reduced B cell lymphopoiesis, reduced myelopoiesis in fe-
tal liver, and virtual absence of myelopoiesis in bone mar-
row described in bGH-Tg mice (38). These in vivo and
in vitro studies could thus lead to the development of spe-
cific pharmacological inhibitors of cytokine and chemo-
kine signaling that are able to interfere with inflammatory
responses.
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Figure 7. Model for cytokine intervention in chemokine responses.
Through interaction with its receptor (GHR), GH induces JAK/STAT
pathway activation, resulting in STAT nuclear translocation and SOCS3
up-regulation. SOCS3 binds to the chemokine receptor (CXCR4); this
interaction is facilitated by receptor dimerization induced by ligand
(CXCL12) binding. As a consequence, chemokine-mediated activation
of JAK/STAT and Gi pathways are impaired and chemokine responses
are blocked.320 SOCS3 Inhibits CXCL12 Signal Transduction
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